Please wait a minute...
文章检索
预防医学  2022, Vol. 34 Issue (12): 1189-1193    DOI: 10.19485/j.cnki.issn2096-5087.2022.12.001
  标准·方案·指南 本期目录 | 过刊浏览 | 高级检索 |
系统性红斑狼疮患者疫苗接种专家共识
浙江省预防医学会风湿病预防与控制专业委员会,浙江 杭州 310003
Expert consensus on vaccination among adult patients withsystemic lupus erythematosus
Rheumatic Disease Prevention and Control Committee, Zhejiang Preventive Medical Association, Hangzhou, Zhejiang 310003, China
全文: PDF(783 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 系统性红斑狼疮(SLE)是慢性自身免疫性疾病,感染是最常见的并发症和死亡原因之一。接种疫苗是SLE患者预防感染的有效手段。浙江省预防医学会风湿病预防与控制专业委员会针对SLE患者接种疫苗预防感染、疫苗种类、接种时机、有效性和安全性以及SLE治疗药物对接种的影响等问题形成此专家共识,以指导风湿科医生和预防接种人员为SLE患者规范接种疫苗,预防感染,提高SLE患者生命质量。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 系统性红斑狼疮预防接种感染共识    
Abstract:Systemic lupus erythematosus (SLE) is a chronic autoimmune disease and infection is one of the most common complications and death causes of SLE. Vaccination is an effective tool for prevention of infections among SLE patients. This expert consensus was achieved by the Rheumatic Disease Prevention and Control Committee, Zhejiang Preventive Medical Association on the prevention of infections with vaccines, types of vaccines, vaccination timing, efficacy and safety of vaccines and impact of therapeutic agents for SLE on vaccinations to guide the rheumatologists and vaccination professionals for scientific and standardized vaccinations among SLE patients, so as to prevent infection and improve quality of life among SLE patients.
Key wordssystemic lupus erythematosus    vaccination    infection    consensus
收稿日期: 2022-10-09      修回日期: 2022-10-24      出版日期: 2022-12-10
中图分类号:  R593.24  
  R186  
通信作者: 杨旭燕,E-mail:hangzhouyxy@zju.edu.cn;胡昱,E-mail:yhu@cdc.zj.cn   
引用本文:   
. 系统性红斑狼疮患者疫苗接种专家共识[J]. 预防医学, 2022, 34(12): 1189-1193.
链接本文:  
http://www.zjyfyxzz.com/CN/Y2022/V34/I12/1189
[1] ZHU T Y,TAM L S,LEE V W,et al.The impact of flare on disease costs of patients with systemic lupus erythematosus[J].Arthritis Rheum,2009,61(9):1159-1167.
[2] ILLESCAS-MONTES R,CORONA-CASTRO C C,MELGUIZO-RODRÍGUEZ L,et al.Infectious processes and systemic lupus erythematosus[J].Immunology,2019,158(3):153-160.
[3] LIU Z,DAVIDSON A.Taming lupus-a new understanding of pathogenesis is leading to clinical advances[J].Nat Med,2012,18(6):871-882.
[4] GATTO M,ZEN M,IACCARINO L,et al.New therapeutic strategies in systemic lupus erythematosus management[J].Nat Rev Rheumatol,2019,15(1):30-48.
[5] RIGANTE D,ESPOSITO S.Infections and systemic lupus erythematosus:binding or sparring partners?[J].Int J Mol Sci,2015,16(8):17331-17343.
[6] PAN Q,LIU Z,LIAO S,et al.Current mechanistic insights into the role of infection in systemic lupus erythematosus[J/OL].Biomed Pharmacother,2019,117[2022-10-24].https://doi.org/10.1016/j.biopha.2019.109122.
[7] RIGANTE D,MAZZONI M B,ESPOSITO S.The cryptic interplay between systemic lupus erythematosus and infections[J].Autoimmun Rev,2014,13(2):96-102.
[8] WU X Y,YANG M,XIE Y S,et al.Causes of death in hospitalized patients with systemic lupus erythematosus:a 10-year multicenter nationwide Chinese cohort[J].Clin Rheumatol,2019,38(1):107-115.
[9] MOK C C.Herpes zoster vaccination in systemic lupus erythematosus:the current status[J].Hum Vaccin Immunother,2019,15(1):45-48.
[10] DAVID E, BELOT A, LEGA J C, et al.Human papillomavirus and systemic lupus erythematosus[J].Rev Med Interne, 2021, 42(7):498-504.
[11] SUN F F,CHEN Y,WU W L,et al.Varicella zoster virus infections increase the risk of disease flares in patients with SLE:a matched cohort study[J/OL].Lupus Sci Med,2019,6(1)[2022-10-24].http://dx.doi.org/10.1136/lupus-2019-000339.
[12] FURER V,RONDAAN C,HEIJSTEK M W,et al.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases[J].Ann Rheum Dis,2020,79(1):39-52.
[13] CORDEIRO I,DUARTE A C,FERREIRA J F,et al.Recommendations for vaccination in adult patients with systemic inflammatory rheumatic diseases from the portuguese society of rheumatology[J].Acta Reumatol Port,2016,41(2):112-130.
[14] AYTAC M B,KASAPCOPUR O,ASLAN M,et al.Hepatitis B vaccination in juvenile systemic lupus erythematosus[J].Clin Exp Rheumatol,2011,29(5):882-886.
[15] MOK C C,HO L Y,FONG L S,et al.Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus:a case-control study[J].Ann Rheum Dis,2013,72(5):659-664.
[16] BOMBARDIER C,GLADMAN D D,UROWITZ M B,et al.Derivation of the SLEDAI.A disease activity index for lupus patients.The Committee on Prognosis Studies in SLE[J].Arthritis Rheum,1992,35(6):630-640.
[17] COOK R J,GLADMAN D D,PERICAK D,et al.Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity[J].J Rheumatol,2000,27(8):1892-1895.
[18] GLADMAN D D,UROWITZ M B,KAGAL A,et al.Accurately describing changes in disease activity in systemic lupus erythematosus[J].J Rheumatol,2000,27(2):377-379.
[19] YEE C S,ISENBERG D A,PRABU A,et al.BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000[J].Ann Rheum Dis,2008,67(6):873-876.
[20] HOLVAST A,HUCKRIEDE A,WILSCHUT J,et al.Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease[J].Ann Rheum Dis,2006,65(7):913-918.
[21] LIPNICK R N,KARSH J,STAHL N I,et al.Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives[J].J Rheumatol,1985,12(6):1118-1121.
[22] KURUMA K A,BORBA E F,LOPES M H,et al.Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus[J].Lupus,2007,16(5):350-354.
[23] HARPAZ R,ORTEGA-SANCHEZ I R,SEWARD J F.Prevention of herpes zoster:recommendations of the Advisory Committee on Immunization Practices(ACIP)[J].MMWR Recomm Rep,2008,57(5):1-30.
[24] FURER V,EVIATAR T,ZISMAN D,et al.Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population:a multicentre study[J].Ann Rheum Dis,2021,80(10):1330-1338.
[25] GARG M,MUFTI N,PALMORE T N,et al.Recommendations and barriers to vaccination in systemic lupus erythematosus[J].Autoimmun Rev,2018,17(10):990-1001.
[26] HUA C, BARNETCHE T, COMBE B, et al.Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta- analysis[J].Arthritis Care Res,2014,66:1016-1026.
[27] RASMUSSEN S L,FUURSTED K,NIELSEN K A,et al.Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status[J].Scand J Rheumatol,2020,49(5):353-360.
[28] HEIJSTEK M W,SCHERPENISSE M,GROOT N,et al.Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis:a prospective controlled observational cohort study[J].Ann Rheum Dis,2014,73(8):1500-1507.
[29] ABU-SHAKRA M,PRESS J,VARSANO N,et al.Specific antibody response after influenza immunization in systemic lupus erythematosus[J].J Rheumatol,2002,29(12):2555-2557.
[30] PAPPAIOANOU M,FISHBEIN D B,DREESEN D W,et al.Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine[J].N Engl J Med,1986,314(5):280-284.
[31] CHATHAM W W,WALLACE D J,STOHL W,et al.Effect of belimumab on vaccine antigen antibodies to influenza,pneumococcal,and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial[J].J Rheumatol,2012,39(8):1632-1640.
[32] BINGHAM C O 3rd,LOONEY R J,DEODHAR A,et al.Immunization responses in rheumatoid arthritis patients treated with rituximab:results from a controlled clinical trial[J].Arthritis Rheum,2010,62(1):64-74.
[33] 浙江省卫生健康委员会.浙江省疫苗接种方案(2021年版)[EB/OL].[2022-10-24].https://wsjkw.zj.gov.cn/art/2021/10/19/art_1229560650_2369617.html.
[34] PAPP K A,HARAOUI B,KUMAR D,et al.Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies[J].J Cutan Med Surg,2019,23(1):50-74.
[35] LOPEZ A,MARIETTE X,BACHELEZ H,et al.Vaccination recommendations for the adult immunosuppressed patient:a systematic review and comprehensive field synopsis[J].J Autoimmun,2017,80:10-27.
[1] 张超, 罗小福, 刘艳, 沈建勇, 徐秦儿, 韩利萍, 马力. 湖州市老年人接种流感灭活疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(8): 701-704.
[2] 段恬筱, 黄希汇, 刘诗川, 胡薇薇, 刘涛, 李亚, 岑斌. 新型冠状病毒感染流行期间医护人员职业倦怠的Meta分析[J]. 预防医学, 2023, 35(6): 526-532.
[3] 周嘉昱, 施剑飞. 新型冠状病毒感染疫情期间医护人员心理问题及干预研究进展[J]. 预防医学, 2023, 35(4): 307-310.
[4] 向泽林, 富小飞, 亓云鹏, 朱国英, 顾伟玲, 胡洁, 李傅冬, 周晚玲, 侯志刚, 刘杨, 刘砚清, 郭飞飞, 陆先权, 郭林杰, 陈中文. 羽毛球场馆一起新型冠状病毒感染聚集性疫情的流行病学调查[J]. 预防医学, 2023, 35(4): 316-319.
[5] 钱晓萍, 罗小福, 凌健. 湖州市疫苗接种相关的过敏性皮疹监测结果[J]. 预防医学, 2023, 35(4): 339-341.
[6] 王炸亚, 叶莉霞, 吴锋. 宁波市2018—2021年出生儿童肠道病毒71型疫苗接种情况分析[J]. 预防医学, 2023, 35(10): 895-898.
[7] 谢家敏, 武婕. 人腺病毒感染的流行病学研究进展[J]. 预防医学, 2023, 35(1): 32-35,40.
[8] 何飞, 马永法, 顾春艳, 潘铭, 陈万庚. 2005—2021年盐都区水痘流行特征[J]. 预防医学, 2023, 35(1): 61-64.
[9] 江伟, 刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 顾雯雯, 张小平. 2017—2021年杭州市HPV疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 71-73,77.
[10] 张超, 沈建勇, 罗小福, 徐秦儿, 韩利萍. 2015—2021年湖州市MMR疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 74-77.
[11] 崔清荣, 胡海燕, 罗赛飞, 阮卫, 庞天兰, 陈丁玲. 天台县农村居民土源性线虫病监测结果[J]. 预防医学, 2022, 34(9): 937-940.
[12] 何亚盛, 张红霞, 倪银, 朱越燕, 彭敏, 杨丹红. 急诊重症监护病房住院患者医院感染的预测模型研究[J]. 预防医学, 2022, 34(9): 919-922.
[13] 龚震宇, 龚训良. 全球消除脊髓灰质炎进展[J]. 预防医学, 2022, 34(8): 861-862.
[14] 孙菲菲, 楼晓红, 虞洪斌. 放射治疗患者医院感染的影响因素分析[J]. 预防医学, 2022, 34(5): 515-518,529.
[15] 雷蓉蓉, 张婷, 吴成果, 罗建奎, 汪清雅, 任昌理. 南川区居民结核潜伏感染调查[J]. 预防医学, 2022, 34(4): 371-374.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed